-
Mashup Score: 1Tislelizumab Maintains Superior Overall Survival Benefit Vs Docetaxel in Pretreated NSCLC - 2 year(s) ago
Patients with previously treated non–small cell lung cancer experienced a median overall survival of 16.9 months with second- or third-line tislelizumab vs 11.9 months with docetaxel.
Source: Oncology Nursing NewsCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
Younger adults with lung cancer had a higher likelihood of having late-stage disease at diagnosis than older adults, according to study results.The findings, presented during International Association for the Study of Lung Cancer World Conference on Lung Cancer, showed differences in tumor biology, delays in diagnosis and the absence of methods to facilitate early detection may contribute to the
Source: www.healio.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
ICYMI: Younger #lungcancer patients more likely to have advanced disease at diagnosis. https://t.co/g29ZQRVvQn @ClevelandClinic @IASLC #LCSM #WCLC22 #HemOnc #Oncology #cancer
-
-
Mashup Score: 1Chemoimmunotherapy Regimen May Offer Survival Benefit in Subgroups of Metastatic NSCLC - The ASCO Post - 2 year(s) ago
The addition of the CTLA-4 inhibitor tremelimumab to durvalumab and chemotherapy in the first-line setting has already demonstrated an overall survival and progression-free survival benefit vs chemotherapy alone in patients with metastatic non–small cell lung cancer (NSCLC). According to data presented at the International Association for the Study of Lung Cancer (IASLC) 2022 World Conference on…
Source: ascopost.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Exploratory Analysis of POSEIDON: Chemoimmunotherapy Regimen May Offer Survival Benefit in Subgroups of Metastatic NSCLC https://t.co/fHK4E8RLRe #WCLC22 #WCLC2022 #LCSM #lungcancer #oncology #immunotherapy
-
-
Mashup Score: 0NELSON vs NLST: Nodule Management Based on Volumetry Shows Increased Benefits - The ASCO Post - 2 year(s) ago
Lung cancer screening has been shown to significantly reduce lung cancer mortality, but some management protocols have more benefit than others, according to data presented at the International Association for the Study of Lung Cancer 2022 World Conference on Lung Cancer (WCLC).1 Although the Dutch-Belgian lung cancer screening trial Nederlands-Leuvens Longkanker Screenings Onderzoek (NELSON)…
Source: ascopost.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
NELSON vs NLST: Nodule Management Based on Volumetry Shows Increased Benefits https://t.co/eibVIcnRPR #LCSM #lungcancer #oncology #WCLC22 #WCLC2022
-
-
Mashup Score: 2IMpower010: Early Survival Data Favor Atezolizumab Over Best Supportive Care in Resected NSCLC With PD-L1 Expression ≥ 50% - The ASCO Post - 2 year(s) ago
Early results from the IMpower010 trial showed an overall survival trend favoring adjuvant atezolizumab vs best supportive care for patients with PD-L1–positive (tumor expression ≥ 1%), stage II–IIIA (UICC/AJCC staging system, 7th ed), resected non–small cell lung cancer (NSCLC). These data were presented at the International Association for the Study of Lung Cancer (IASLC) 2022 World Conference…
Source: ascopost.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
IMpower010: Early Survival Data Favor Atezolizumab Over Best Supportive Care in Resected NSCLC With PD-L1 Expression ≥ 50% https://t.co/ZdXfafALzW #LCSM #lungcancer #immunotherapy #oncology #WCLC22 #WCLC2022
-
-
Mashup Score: 1NADIM Trial: Neoadjuvant Chemoimmunotherapy Improved Survival in Resectable, Stage IIIA NSCLC - The ASCO Post - 2 year(s) ago
In patients with resectable, stage IIIA non–small cell lung cancer (NSCLC), the addition of neoadjuvant nivolumab to platinum-based chemotherapy significantly improved overall survival compared with neoadjuvant chemotherapy alone, according to data presented by Mariano Provencio, MD, PhD, at the International Association for the Study of Lung Cancer (IASLC) 2022 World Conference on Lung Cancer…
Source: ascopost.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
NADIM Trial: Neoadjuvant Chemoimmunotherapy Improved Survival in Resectable, Stage IIIA NSCLC https://t.co/YUTXLQhUT7 #LCSM #lungcancer #oncology #immunotherapy #WCLC22 #WCLC2022
-
-
Mashup Score: 0IASLC - 2 year(s) ago
Login to access our full site!LOGIN
Source: IASLCCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
WELCOME to Day 2 of #NACLC22! Today's program hosts education sessions on Immunotherapy, #SCLC & #WCLC22 Updates in Thoracic Oncology, Translational Science, Early Detection, Nodule Management and more! Join us live or virtually at https://t.co/bl6qXbOwKo https://t.co/OVO60te8OW
-
-
Mashup Score: 0Data Supports Smoking Cessation as Part Active Lung Cancer Treatment - ILCN.org (ILCN/WCLC) - 2 year(s) ago
Experts reviewed data that show smoking can reduce innate immunity and suppress the efficacy of anti-cancer agents, leading to poorer outcomes for patients who continue to smoke after their cancer diagnosis.
Source: ILCN.org (ILCN/WCLC)Categories: Hem/Onc News and Journals, Latest HeadlinesTweet-
ICYMI at #WCLC22: Experts explored several important tobacco related topics that #lungcancer clinicians need to know. Read a recap in ILCN: https://t.co/MPz2hoGc7c #LCSM
-
-
Mashup Score: 1Real-World Experience With Durvalumab at the Mayo Clinic Mirrors PACIFIC Findings - The ASCO Post - 2 year(s) ago
By Caroline Helwick Posted: 9/19/2022 10:18:00 AM Last Updated: 9/19/2022 1:45:15 PM Concurrent chemoradiation followed by durvalumab has become the standard of care in patients with unresectable, locally advanced non–small cell lung cancer (NSCLC), based on the PACIFIC trial.1 But clinical trials have…
Source: ascopost.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Real-World Experience With Durvalumab at the Mayo Clinic Mirrors PACIFIC Findings https://t.co/vLTTAU7AMz #LCSM #lungcancer #WCLC22 #WCLC2022 @IASLC #oncology #immunotherapy
-
-
Mashup Score: 1Get Up to Date on SCLC Brain Metastases, Neuroendocrine Tumors - ILCN.org (ILCN/WCLC) - 2 year(s) ago
Experts evaluate available evidence comparing various strategies, including prophylactic cranial irradiation vs. surveillance, stereotactic radiosurgery vs. whole-brain radiotherapy, and more.
Source: ILCN.org (ILCN/WCLC)Categories: Hem/Onc News and Journals, Latest HeadlinesTweet-
ICYMI at #WCLC22: Presenters discussed optimizing the management of SCLC and neuroendocrine tumors. Read a recap in ILCN: https://t.co/RFzywRV1P7 @alvaroquintanal #LCSM
-
Tislelizumab Maintains Superior Overall Survival Benefit Vs Docetaxel in Pretreated #NSCLC #lcsm #lungcancer #oncologynursing #oncology #WCLC22 https://t.co/pWJQKlof1o